Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322697531> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4322697531 endingPage "1836" @default.
- W4322697531 startingPage "1836" @default.
- W4322697531 abstract "<h3>Objective.</h3> —To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. <h3>Study Design.</h3> —Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. <h3>Population.</h3> —A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. <h3>Outcome Measure.</h3> —Twenty-eight—day all-cause mortality. <h3>Results.</h3> —There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n=893; generalized Wilcoxon statistic,<i>P</i>=.22) or among patients with shock at study entry (n=713; generalized Wilcoxon statistic,<i>P</i>=.23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n=563; linear dose-response,<i>P</i>=.009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n=580; linear dose-response,<i>P</i>=.005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n=411; linear dose-response,<i>P</i>=.002). <h3>Conclusions.</h3> —There was not a statistically significant increase in survivial time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater. (<i>JAMA</i>. 1994;271:1836-1843)" @default.
- W4322697531 created "2023-03-02" @default.
- W4322697531 creator A5074439882 @default.
- W4322697531 date "1994-06-15" @default.
- W4322697531 modified "2023-10-10" @default.
- W4322697531 title "Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome" @default.
- W4322697531 doi "https://doi.org/10.1001/jama.1994.03510470040032" @default.
- W4322697531 hasPublicationYear "1994" @default.
- W4322697531 type Work @default.
- W4322697531 citedByCount "560" @default.
- W4322697531 countsByYear W43226975312012 @default.
- W4322697531 countsByYear W43226975312013 @default.
- W4322697531 countsByYear W43226975312014 @default.
- W4322697531 countsByYear W43226975312015 @default.
- W4322697531 countsByYear W43226975312016 @default.
- W4322697531 countsByYear W43226975312017 @default.
- W4322697531 countsByYear W43226975312018 @default.
- W4322697531 countsByYear W43226975312019 @default.
- W4322697531 countsByYear W43226975312020 @default.
- W4322697531 countsByYear W43226975312021 @default.
- W4322697531 countsByYear W43226975312022 @default.
- W4322697531 countsByYear W43226975312023 @default.
- W4322697531 crossrefType "journal-article" @default.
- W4322697531 hasAuthorship W4322697531A5074439882 @default.
- W4322697531 hasConcept C126322002 @default.
- W4322697531 hasConcept C142724271 @default.
- W4322697531 hasConcept C149892131 @default.
- W4322697531 hasConcept C170493617 @default.
- W4322697531 hasConcept C204787440 @default.
- W4322697531 hasConcept C27081682 @default.
- W4322697531 hasConcept C2776885963 @default.
- W4322697531 hasConcept C2777628635 @default.
- W4322697531 hasConcept C2778122271 @default.
- W4322697531 hasConcept C2778384902 @default.
- W4322697531 hasConcept C2908647359 @default.
- W4322697531 hasConcept C71924100 @default.
- W4322697531 hasConcept C90924648 @default.
- W4322697531 hasConcept C99454951 @default.
- W4322697531 hasConceptScore W4322697531C126322002 @default.
- W4322697531 hasConceptScore W4322697531C142724271 @default.
- W4322697531 hasConceptScore W4322697531C149892131 @default.
- W4322697531 hasConceptScore W4322697531C170493617 @default.
- W4322697531 hasConceptScore W4322697531C204787440 @default.
- W4322697531 hasConceptScore W4322697531C27081682 @default.
- W4322697531 hasConceptScore W4322697531C2776885963 @default.
- W4322697531 hasConceptScore W4322697531C2777628635 @default.
- W4322697531 hasConceptScore W4322697531C2778122271 @default.
- W4322697531 hasConceptScore W4322697531C2778384902 @default.
- W4322697531 hasConceptScore W4322697531C2908647359 @default.
- W4322697531 hasConceptScore W4322697531C71924100 @default.
- W4322697531 hasConceptScore W4322697531C90924648 @default.
- W4322697531 hasConceptScore W4322697531C99454951 @default.
- W4322697531 hasIssue "23" @default.
- W4322697531 hasLocation W43226975311 @default.
- W4322697531 hasOpenAccess W4322697531 @default.
- W4322697531 hasPrimaryLocation W43226975311 @default.
- W4322697531 hasRelatedWork W1983350655 @default.
- W4322697531 hasRelatedWork W2030171828 @default.
- W4322697531 hasRelatedWork W2031364456 @default.
- W4322697531 hasRelatedWork W2076624509 @default.
- W4322697531 hasRelatedWork W2136208369 @default.
- W4322697531 hasRelatedWork W2386082860 @default.
- W4322697531 hasRelatedWork W2414367703 @default.
- W4322697531 hasRelatedWork W3029322182 @default.
- W4322697531 hasRelatedWork W17630582 @default.
- W4322697531 hasRelatedWork W2430611441 @default.
- W4322697531 hasVolume "271" @default.
- W4322697531 isParatext "false" @default.
- W4322697531 isRetracted "false" @default.
- W4322697531 workType "article" @default.